Aims The objective of the present analysis was to systematically examine the effect of
intracoronary bone marrow cell (BMC) therapy on left ventricular (LV) function after ST …

Objectives: Our aim was to investigate the safety and efficacy of intravenous allogeneic
human mesenchymal stem cells (hMSCs) in patients with myocardial infarction (MI) …

Background Clinical impact of atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM) is
largely unresolved. Thus, we analyzed the prognostic implications of AF in a large …

Background—A growing population of patients with coronary artery disease experiences
angina that is not amenable to revascularization and is refractory to medical therapy …

Background—Percutaneous coronary intervention (PCI) for ST-elevation myocardial
infarction (STEMI) is superior to fibrinolysis when performed in a timely manner in high …

Rationale: A growing number of patients with coronary disease have refractory angina.
Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous …

Context Previous studies using autologous bone marrow mononuclear cells (BMCs) in
patients with ischemic cardiomyopathy have demonstrated safety and suggested efficacy …

Context Clinical trial results suggest that intracoronary delivery of autologous bone marrow
mononuclear cells (BMCs) may improve left ventricular (LV) function when administered …

Context While the delivery of cell therapy after ST-segment elevation myocardial infarction
(STEMI) has been evaluated in previous clinical trials, the influence of the timing of cell …

Rationale: The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared
collaborative multinational database, including individual data of patients with ischemic …